This article explores how advanced technologies and regulatory demands are transforming cell line development, crucial for biopharmaceutical production.

Richard Hammond shares expert views on the importance of demonstrating monoclonality to meet FDA and EMA requirements, and the need to adopt cutting-edge techniques for ensuring product safety, consistency, and efficacy.

The discussion also covers the economic impact of early identification of high-producing cell lines to enhance productivity and reduce development costs. Droplet-based microfluidic technology, such as the Cyto-Mine platform, is highlighted for improving workflow efficiency and maintaining cell viability by minimizing shear stress during processing.

* In 2025, Sphere Fluidics became Sphere Bio. References to Sphere Fluidics in this article reflect our former name prior to rebranding.

For more insights on the latest developments in biologics and cell line research, visit Sphere Bio’s Knowledge Hub or or dive into our Cyto-Mine® Chroma solution for early-stage screening.

This article is part of our Editorial Coverage series, showcasing Sphere Bio’s thought leadership and technological contributions in top-tier industry publications. Stay tuned for more.